|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.
100 Clinical Results associated with Triphase Research and Development III Corp.
0 Patents (Medical) associated with Triphase Research and Development III Corp.
100 Deals associated with Triphase Research and Development III Corp.
100 Translational Medicine associated with Triphase Research and Development III Corp.